GILD vs PFE: fair value comparison
Gilead Sciences, Inc. and Pfizer Inc. · Updated 2026-09-07
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PFE currently sits closer to the top of our discount ranking. GILD carries the stronger quality grade.
| GILD | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $151.00 | $28.45 |
| 12-month range | $119.79–$150.03 | $24.23–$28.55 |
| Sector rank | #104 of 113 Healthcare | #101 of 113 Healthcare |
| Quality grade | D | F |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: GILD fair value analysis · PFE fair value analysis